Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$6.69 USD
+0.41 (6.53%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $6.72 +0.03 (0.45%) 4:24 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for Foghorn Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -98.43 | -108.88 | -101.32 | -68.80 | -51.13 |
Depreciation/Amortization & Depletion | 0.80 | 2.03 | 3.41 | 1.33 | 0.69 |
Net Change from Assets/Liabilities | -41.88 | 281.55 | 33.44 | 28.70 | 1.20 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 21.40 | 18.92 | 14.22 | 7.49 | 2.90 |
Net Cash From Operating Activities | -118.11 | 193.61 | -50.25 | -31.29 | -46.34 |
Property & Equipment | -1.22 | -1.21 | -3.31 | -15.93 | -0.96 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 145.67 | -243.11 | 39.49 | -92.98 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 144.45 | -244.32 | 36.17 | -108.91 | -0.96 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.78 | 1.76 | 1.42 | 91.08 | 15.99 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | -21.21 | -15.53 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 42.21 | 141.92 | 7.98 |
Net Cash from Financing Activities | 1.78 | 1.76 | 22.42 | 217.47 | 23.97 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 28.12 | -48.95 | 8.34 | 77.27 | -23.33 |
Cash at Beginning of Period | 53.92 | 102.87 | 94.53 | 17.26 | 40.59 |
Cash at End of Period | 82.04 | 53.92 | 102.87 | 94.53 | 17.26 |
Diluted Net EPS | -2.34 | -2.62 | -2.73 | -6.23 | NA |
Fiscal Year End for Foghorn Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -98.43 | -74.32 | -59.98 | -30.49 | -108.88 |
Depreciation/Amortization & Depletion | 0.80 | 0.44 | 0.23 | 0.09 | 2.03 |
Net Change from Assets/Liabilities | -41.88 | -33.64 | -15.15 | -6.55 | 281.55 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 21.40 | 16.95 | 11.53 | 5.77 | 18.92 |
Net Cash From Operating Activities | -118.11 | -90.57 | -63.36 | -31.18 | 193.61 |
Property & Equipment | -1.22 | -1.19 | -1.11 | -0.64 | -1.21 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 145.67 | 108.25 | 69.74 | 30.14 | -243.11 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 144.45 | 107.07 | 68.64 | 29.51 | -244.32 |
Uses of Funds
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.78 | 1.59 | 0.21 | 0.10 | 1.76 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 1.78 | 1.59 | 0.21 | 0.10 | 1.76 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 28.12 | 18.09 | 5.49 | -1.57 | -48.95 |
Cash at Beginning of Period | 53.92 | 53.92 | 53.92 | 53.92 | 102.87 |
Cash at End of Period | 82.04 | 72.01 | 59.41 | 52.35 | 53.92 |
Diluted Net EPS | -0.57 | -0.34 | -0.70 | -0.73 | -0.69 |